183 related articles for article (PubMed ID: 33862193)
1. Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates.
Weidolf L; Björkbom A; Dahlén A; Elebring M; Gennemark P; Hölttä M; Janzén D; Li X; Andersson S
Drug Discov Today; 2021 Oct; 26(10):2244-2258. PubMed ID: 33862193
[TBL] [Abstract][Full Text] [Related]
2. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
4. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Metabolite Profiles of an
Li XQ; Elebring M; Dahlén A; Weidolf L
Drug Metab Dispos; 2023 Oct; 51(10):1350-1361. PubMed ID: 37429729
[TBL] [Abstract][Full Text] [Related]
6. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
Quemener AM; Centomo ML; Sax SL; Panella R
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851
[TBL] [Abstract][Full Text] [Related]
7. Hybridization Liquid Chromatography-Tandem Mass Spectrometry: An Alternative Bioanalytical Method for Antisense Oligonucleotide Quantitation in Plasma and Tissue Samples.
Li P; Gong Y; Kim J; Liu X; Gilbert J; Kerns HM; Groth R; Rooney M
Anal Chem; 2020 Aug; 92(15):10548-10559. PubMed ID: 32628461
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
[TBL] [Abstract][Full Text] [Related]
9. Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides.
Nikan M; Tanowitz M; Dwyer CA; Jackson M; Gaus HJ; Swayze EE; Rigo F; Seth PP; Prakash TP
J Med Chem; 2020 Aug; 63(15):8471-8484. PubMed ID: 32677436
[TBL] [Abstract][Full Text] [Related]
10. Antisense drug discovery and development technology considered in a pharmacological context.
Crooke ST; Liang XH; Crooke RM; Baker BF; Geary RS
Biochem Pharmacol; 2021 Jul; 189():114196. PubMed ID: 32800852
[TBL] [Abstract][Full Text] [Related]
11. High-sensitivity quantification of antisense oligonucleotides for pharmacokinetic characterization.
Mahajan S; Zhao H; Kovacina K; Lachacz E; Hoxha S; Chan J; Liang M
Bioanalysis; 2022 May; 14(9):603-613. PubMed ID: 35578971
[TBL] [Abstract][Full Text] [Related]
12. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle.
Prakash TP; Mullick AE; Lee RG; Yu J; Yeh ST; Low A; Chappell AE; Østergaard ME; Murray S; Gaus HJ; Swayze EE; Seth PP
Nucleic Acids Res; 2019 Jul; 47(12):6029-6044. PubMed ID: 31127296
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of antisense oligonucleotides to pancreatic β-cells.
Ämmälä C; Drury WJ; Knerr L; Ahlstedt I; Stillemark-Billton P; Wennberg-Huldt C; Andersson EM; Valeur E; Jansson-Löfmark R; Janzén D; Sundström L; Meuller J; Claesson J; Andersson P; Johansson C; Lee RG; Prakash TP; Seth PP; Monia BP; Andersson S
Sci Adv; 2018 Oct; 4(10):eaat3386. PubMed ID: 30345352
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
17. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
[TBL] [Abstract][Full Text] [Related]
19. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
20. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
